July 5, 2006

• In the Matter of Fresenius AG; File No. 051 0154, Docket No. C-4159

June 20, 2006

• The Non-Profit Institutions Act Exemption From the Robinson-Patman Act: Bureau of Competition Staff Advisory Opinion to Alpena Public Schools, of Alpena, Michigan, Concerning Whether A Prescription-Drug Benefit Program Proposed By the School District Would Fall Within the Non-Profit Institutions Act.
  • Text of the Staff Advisory Opinion, From Assistant Director Markus H. Meier
  • News Release

April 24, 2006

• Bureau of Competition Issues FY 2005 Summary of Pharmaceutical Company Settlement Agreements

April 21, 2006

• For Your Information: April 21, 2006
  Commission Approves Final Consent Order in Matter of Allergan/Inamed
  Following a public comment period, the Commission has approved the issuance of a final consent order in the matter concerning Allergan, Inc.’s acquisition of Inamed Corporation

March 30, 2006

• Maintaining Competition, FTC Allows Fresenius’ $3.5 Billion Deal to Buy Rival Dialysis Provider Renal Care Group
  Settlement Requires the Sale of 91 Dialysis Clinics and Interest in 12 More in 66 Areas Across the United States
  

March 29, 2006

• FTC Proposes Study of Competitive Impacts of Authorized Generic Drugs

March 28, 2006

• Hospitals’ Plan for Collective Bargaining of Physicians’ Fees Likely Would Violate Federal Laws, FTC Staff Says
  

March 8, 2006

• Preserving Competition, FTC Requires Divestiture Before Allowing Allergan’s Acquisition of Inamed
  Consent Order Requires Allergan to Divest Future Botox Rival Reloxin in $3.2 Billion Deal
  

March 7, 2006

• For Your Information:
  FTC Staff Files Comments on New Jersey’s Proposed Advertising Guideline 4; Commission Finalizes Teva/Ivax Consent Order
  The Commission has authorized the staffs of the Bureau of Consumer Protection, Bureau of Economics, and Office of Policy Planning to file a letter with the New Jersey Supreme Court Committee on Attorney Advertising regarding Proposed Advertising Guideline 4, which would place certain restrictions on the use by lawyers or law firms of endorsements or testimonials from clients.; Following a public comment period, the Commission has approved a final order related to Teva Pharmaceutical Industries Ltd.’s recent acquisition of Ivax Corporation

February 13, 2006

• Texas Doctors' IPA Agrees to Settle Price Fixing Charges

February 7, 2006

• For Your Information: February 7, 2006
  Davita Inc. Submits Petition for Approval of Proposed Divestiture; FTC Submits Budget Request and Performance Plans to Congress
  The Commission has received a petition from DaVita Inc. (DaVita) requesting approval of a proposed divestiture related to its recent acquisition of Gambro Healthcare (Gambro).; The Commission has approved the following documents: 1) the FTC’s FY 2007 Budget Overview Statement; 2) the Government Performance and Results Act (GPRA) Performance Plans for FY 2006 and FY 2007; and 3) an Update of the President’s Management Agenda Exhibit; The Commission has approved the following documents: 1) the FTC’s FY 2007 Budget Overview Statement; 2) the Government Performance and Results Act (GPRA) Performance Plans for FY 2006 and FY 2007; and 3) an Update of the President’s Management Agenda Exhibit

January 23, 2006

• Preserving Competition, FTC Requires Divestitures Before Allowing Teva’s $7.4 Billion Acquisition of IVAX
  Consent Order Requires Divestitures in 15 Generic Drug Markets

COMMISSION ACTIONS

April 21, 2006

• In the Matter of Allergan, Inc., and Inamed Corporation, File No. 061 0031, Docket No. C-4156

March 30, 2006

• In the Matter of Fresenius AG; File No. 051 0154, Docket No. C-4159
                          

March 29, 2006

• Consideration of Authorized Generic Drug Study: Solicitation of Public Comments on Proposed Information Requests to Firms in the Prescription Drug Industry
  • Text of the Federal Register Notice
  • News Release

March 28, 2006

• Suburban Health Organization
  Letter from David R. Pender to Clifton E. Johnson and William H. Thompson, dated March 28, 2006, concerning the antitrust implications of a proposal to undertake a program involving partial integration among eight independent Suburban Health Organization member hospitals and the 192 primary care physicians that, in total, they employ.
  
• In the Matter of Health Care Alliance of Laredo, L.C. File No. 041 0097

March 8, 2006

• In the Matter of Allergan, Inc., and Inamed Corporation, File No. 061 0031, Docket No. C-4156
  • News Release

March 7, 2006

• In the Matter of Teva Pharmaceutical Industries Ltd., and IVAX Corporation, File No. 051-0214, Docket No. C-4155
  • News Release

February 13, 2006

• In the Matter of Health Care Alliance of Laredo, L.C., File No. 041 0097

February 7, 2006

• In the Matter of DaVita, Inc., File No. 051 0051, Docket No. C-4152

January 23, 2006

• In the Matter of Teva Pharmaceutical Industries Ltd., and IVAX Corporation, File No. 051 0214, Docket No. C-4155